Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
Kim C, Xi L, Cultraro CM, Wei F, Jones G, Cheng J, Shafiei A, Pham TH, Roper N, Akoth E, Ghafoor A, Misra V, Monkash N, Strom C, Tu M, Liao W, Chia D, Morris C, Steinberg SM, Bagheri H, Wong DTW, Raffeld M, Guha U. Kim C, et al. Among authors: morris c. Cancers (Basel). 2021 Jul 3;13(13):3342. doi: 10.3390/cancers13133342. Cancers (Basel). 2021. PMID: 34283064 Free PMC article.
Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Pritchett MA, Camidge DR, Patel M, Khatri J, Boniol S, Friedman EK, Khomani A, Dalia S, Baker-Neblett K, Plagnol V, Howarth KD, Jones GR, Rosenfeld N, Morris CD, Govindan R. Pritchett MA, et al. JCO Precis Oncol. 2019 Apr 25;3:PO.18.00299. doi: 10.1200/PO.18.00299. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914040 Free PMC article.
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.
Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, Besse B. Aldea M, et al. Among authors: morris c. J Thorac Oncol. 2020 Mar;15(3):383-391. doi: 10.1016/j.jtho.2019.11.024. Epub 2019 Dec 13. J Thorac Oncol. 2020. PMID: 31843682 Free article.
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.
Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D. Ortiz-Cuaran S, et al. Among authors: morris c. Clin Cancer Res. 2020 Dec 1;26(23):6242-6253. doi: 10.1158/1078-0432.CCR-20-1037. Epub 2020 Aug 28. Clin Cancer Res. 2020. PMID: 32859654
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar SN, Pepin K, Ward JP, Botticella A, Howarth K, Knape C, Morris C, Govindan R, Besse B, Morgensztern D. Knapp B, et al. Among authors: morris c. Front Oncol. 2022 Mar 28;12:856132. doi: 10.3389/fonc.2022.856132. eCollection 2022. Front Oncol. 2022. PMID: 35419282 Free PMC article.
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Plagnol V, Woodhouse S, Howarth K, Lensing S, Smith M, Epstein M, Madi M, Smalley S, Leroy C, Hinton J, de Kievit F, Musgrave-Brown E, Herd C, Baker-Neblett K, Brennan W, Dimitrov P, Campbell N, Morris C, Rosenfeld N, Clark J, Gale D, Platt J, Calaway J, Jones G, Forshew T. Plagnol V, et al. Among authors: morris c. PLoS One. 2018 Mar 15;13(3):e0193802. doi: 10.1371/journal.pone.0193802. eCollection 2018. PLoS One. 2018. PMID: 29543828 Free PMC article.
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J, Swalduz A, Planchard D, Ortiz-Cuaran S, Mezquita L, Lacroix L, Jovelet C, Rouleau E, Leonce C, De Kievit F, Morris C, Jones G, Mercier K, Howarth K, Green E, Pérol M, Saintigny P, Besse B. Remon J, et al. Among authors: morris c. PLoS One. 2020 Jun 11;15(6):e0234302. doi: 10.1371/journal.pone.0234302. eCollection 2020. PLoS One. 2020. PMID: 32525942 Free PMC article.
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.
Mezquita L, Swalduz A, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, Avrillon V, Recondo G, Marteau S, Benitez JC, De Kievit F, Plagnol V, Lacroix L, Odier L, Rouleau E, Fournel P, Caramella C, Tissot C, Adam J, Woodhouse S, Nicotra C, Auclin E, Remon J, Morris C, Green E, Massard C, Pérol M, Friboulet L, Besse B, Saintigny P. Mezquita L, et al. Among authors: morris c. JCO Precis Oncol. 2020 Apr 2;4:PO.19.00281. doi: 10.1200/PO.19.00281. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923908 Free PMC article.
4,294 results